Cargando…

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan

Evidence of BNT126b2 vaccine effectiveness and breakthrough has been primarily demonstrated in populations outside of Asia; studies in the Western Pacific region are limited. Our retrospective cohort study assessed SARS-CoV-2 cases after vaccine rollout starting from mid-March 2021 at a tertiary hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naito, Toshio, Yan, Yan, Tabe, Yoko, Seyama, Kuniaki, Deshpande, Gautam A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Coronavirus – Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500301/ https://www.ncbi.nlm.nih.gov/pubmed/34614387 http://dx.doi.org/10.1080/21645515.2021.1984124

Ejemplares similares

Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan
por: Saita, Mizue, et al.
Publicado: (2022)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan
por: Yan, Yan, et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
por: Hickey, Thomas E., et al.
Publicado: (2023)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick DMC., et al.
Publicado: (2023)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo
por: Igawa, Gene, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
por: Katoto, Patrick D. M. C., et al.
Publicado: (2022)

A rapid increase in the COVID-19 vaccination rate during the Olympic and Paralympic Games 2021 in Japan
por: Mori, Hirotake, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro’s syndrome: A case report
por: Moscara, Lorenza, et al.
Publicado: (2022)

Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
por: Chen, Yanxia, et al.
Publicado: (2022)

Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey
por: Qin, Shijie, et al.
Publicado: (2023)

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response
por: Mileto, D., et al.
Publicado: (2021)

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
por: Nomura, Jun, et al.
Publicado: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy
por: Ripabelli, Giancarlo, et al.
Publicado: (2022)

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections
por: Saade, Carla, et al.
Publicado: (2022)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
por: Shao, Weihao, et al.
Publicado: (2022)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
por: Wang, Haomeng, et al.
Publicado: (2022)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tpr9cv1ehph3i2tab94k4dr3g5